Mylan's $465M EpiPen Deal With DOJ Too Lenient, Sen. Says
The federal government should reject a $465 million settlement with Mylan NV ending allegations that the company underpaid Medicaid rebates for its EpiPen, Sen. Richard Blumenthal, D-Conn., said on Friday, arguing...To view the full article, register now.
Already a subscriber? Click here to view full article